Valuation: Ind-Swift Laboratories Limited

Market Cap 31.24B 329M 293M 271M 247M 466M 473M 3.26B 1.28B 16.3B 1.24B 1.21B 51.97B P/E 2025
2.38x
P/E 2026 26.1x
Enterprise Value 27.03B 285M 253M 235M 213M 403M 409M 2.82B 1.11B 14.1B 1.07B 1.05B 44.96B EV / Sales 2025
0.12x
EV / Sales 2026 1.11x
Free-Float
33.96%
Yield 2025 *
-
Yield 2026 -
1 day-1.73%
1 week-2.22%
Current month-9.18%
1 month-6.95%
3 months+50.88%
6 months+154.18%
Current year+300.51%
1 week 345
Extreme 345
377.2
1 month 345
Extreme 345
424.75
Current year 87.25
Extreme 87.25
424.75
1 year 87.15
Extreme 87.15
424.75
3 years 68.72
Extreme 68.72
424.75
5 years 52.65
Extreme 52.65
424.75
10 years 15
Extreme 15
424.75
Manager TitleAgeSince
Chief Executive Officer 46 -
Chief Executive Officer 44 2011-06-14
Director of Finance/CFO - 2018-09-28
Director TitleAgeSince
Director/Board Member 44 -
Chairman 74 -
Director/Board Member 35 2010-03-22
Date Insider Type Main position Quantity % Market Cap. Importance
9/12/24 Sell

Chief Financial Officer

30,000 0.0508%
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%-2.22%+236.82%+288.39% 329M
+0.43%+6.59%+56.57%+107.01% 1,120B
+0.90%-2.25%+32.26%+67.33% 616B
+0.71%+3.24%+24.33%+91.20% 504B
-0.13%+5.98%+33.66%+52.01% 367B
+0.52%+0.24%+72.13%+43.10% 360B
-0.95%+4.70%+19.65%+43.09% 288B
-1.98%+3.73%-0.89%+17.28% 258B
-0.35%+4.25%+44.74%+52.51% 234B
-0.75%+3.32%+27.18%+96.05% 194B
Average -0.33%+2.93%+54.65%+85.80% 394.12B
Weighted average by Cap. +0.13%+3.52%+39.35%+73.53%

Financials

2025 2026
Net sales 5.62B 59.19M 52.61M 48.76M 44.37M 83.72M 85.06M 586M 230M 2.93B 222M 217M 9.34B 6.49B 68.4M 60.8M 56.35M 51.27M 96.75M 98.3M 677M 266M 3.39B 257M 251M 10.8B
Net income 2.5B 26.39M 23.46M 21.74M 19.78M 37.33M 37.93M 261M 102M 1.31B 99.05M 96.94M 4.17B 431M 4.54M 4.04M 3.74M 3.41M 6.43M 6.53M 45M 17.64M 225M 17.05M 16.69M 717M
Net Debt -4.27B -44.94M -39.95M -37.03M -33.69M -63.57M -64.59M -445M -175M -2.23B -169M -165M -7.1B -4.21B -44.39M -39.45M -36.57M -33.27M -62.78M -63.79M -440M -172M -2.2B -167M -163M -7.01B
Projected Income Statement - Annual - Ind-Swift Laboratories Limited
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,388
Date Price Change Volume
26-10-18 ₹355.60 -1.02% 10,932
26-10-16 ₹359.25 +0.36% 309,979
26-10-15 ₹357.95 -3.18% 262,152
26-10-14 ₹369.70 +2.31% 354,561
26-10-13 ₹361.35 +0.08% 365,436
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock